U.S. Patent Disclosures
Monday, December 19, 2011
Fate Therapeutics Inc., of San Diego, was granted U.S. Patent No. 8,044,201, titled "Stem Cell Cultures," which claims Thiazovivin, a small-molecule Rho-associated kinase inhibitor, as well as compositions and cell culture media comprising Thiazovivin.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.